Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.

Takafumi MieTakashi SasakiTakeshi OkamotoTsuyoshi TakedaChinatsu MoriTakaaki FurukawaAkiyoshi KasugaMasato MatsuyamaMasato OzakaNaoki Sasahira

Published in: Japanese journal of clinical oncology (2022)

There was no significant difference in efficacy between nal-IRI plus 5-FU/LV and mFFX after GnP. Nal-IRI plus 5-FU/LV appears to be a viable alternative to mFFX as second-line treatment after GnP.

Keyphrases

locally advanced
squamous cell carcinoma
small cell lung cancer
rectal cancer
replacement therapy